Edwards Lifesciences (EW)
(Delayed Data from NYSE)
$67.26 USD
-0.27 (-0.40%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $67.21 -0.05 (-0.07%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for Edwards Lifesciences Corporation falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 1,645 | 1,215 | 1,467 | 1,403 | 1,517 |
Receivables | 837 | 699 | 665 | 603 | 599 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 1,168 | 876 | 727 | 802 | 641 |
Other Current Assets | 386 | 306 | 322 | 283 | 227 |
Total Current Assets | 4,036 | 3,096 | 3,181 | 3,091 | 2,984 |
Net Property & Equipment | 1,749 | 1,633 | 1,547 | 1,395 | 1,060 |
Investments & Advances | 584 | 1,239 | 1,834 | 802 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 586 |
Deferred Charges | 755 | 484 | 247 | 231 | 172 |
Intangibles | 1,682 | 1,450 | 1,492 | 1,505 | 1,504 |
Deposits & Other Assets | 464 | 299 | 111 | 120 | 102 |
Total Assets | 9,363 | 8,293 | 8,503 | 7,237 | 6,488 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 201 | 202 | 205 | 197 | 180 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 969 | 795 | 802 | 670 | 697 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 1,195 | 1,022 | 1,032 | 894 | 902 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 597 | 596 | 596 | 595 | 594 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 778 | 798 | 970 | 1,101 | 784 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 2,644 | 2,486 | 2,667 | 2,663 | 2,340 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 651 | 646 | 642 | 636 | 218 |
Capital Surplus | 2,274 | 1,969 | 1,700 | 1,438 | 1,623 |
Retained Earnings | 8,992 | 7,590 | 6,068 | 4,565 | 3,742 |
Other Equity | -173 | -255 | -158 | -161 | -156 |
Treasury Stock | 5,025 | 4,144 | 2,417 | 1,904 | 1,279 |
Total Shareholder's Equity | 6,719 | 5,807 | 5,836 | 4,574 | 4,148 |
Total Liabilities & Shareholder's Equity | 9,363 | 8,293 | 8,503 | 7,237 | 6,488 |
Total Common Equity | 6,719 | 5,807 | 5,836 | 4,574 | 4,148 |
Shares Outstanding | 606.50 | 618.20 | 624.30 | 623.20 | 625.70 |
Book Value Per Share | 11.08 | 9.39 | 9.35 | 7.34 | 6.63 |
Fiscal Year End for Edwards Lifesciences Corporation falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 1,990 | 1,698 | 1,645 | 1,864 | 1,509 |
Receivables | 834 | 877 | 837 | 802 | 817 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 1,025 | 1,207 | 1,168 | 1,032 | 980 |
Other Current Assets | 667 | 389 | 386 | 369 | 341 |
Total Current Assets | 4,516 | 4,171 | 4,036 | 4,068 | 3,647 |
Net Property & Equipment | 1,640 | 1,768 | 1,749 | 1,681 | 1,662 |
Investments & Advances | 353 | 456 | 584 | 705 | 856 |
Other Non-Current Assets | 307 | 0 | 0 | 0 | 0 |
Deferred Charges | 833 | 777 | 755 | 652 | 611 |
Intangibles | 1,568 | 1,700 | 1,682 | 1,727 | 1,731 |
Deposits & Other Assets | 790 | 768 | 464 | 447 | 412 |
Total Assets | 10,099 | 9,736 | 9,363 | 9,371 | 9,004 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 186 | 212 | 201 | 191 | 193 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 902 | 874 | 969 | 1,024 | 940 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 107 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 1,217 | 1,111 | 1,195 | 1,239 | 1,157 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 597 | 597 | 597 | 597 | 597 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 706 | 778 | 738 | 740 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 2,595 | 2,550 | 2,644 | 2,644 | 2,558 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 654 | 652 | 651 | 650 | 649 |
Capital Surplus | 2,476 | 2,380 | 2,274 | 2,211 | 2,146 |
Retained Earnings | 9,711 | 9,344 | 8,992 | 8,623 | 8,238 |
Other Equity | -153 | -165 | -173 | -181 | -185 |
Treasury Stock | 5,183 | 5,025 | 5,025 | 4,576 | 4,401 |
Total Shareholder's Equity | 7,505 | 7,186 | 6,719 | 6,727 | 6,447 |
Total Liabilities & Shareholder's Equity | 10,099 | 9,736 | 9,363 | 9,371 | 9,004 |
Total Common Equity | 7,505 | 7,186 | 6,719 | 6,727 | 6,447 |
Shares Outstanding | 602.40 | 602.60 | 606.50 | 606.50 | 607.90 |
Book Value Per Share | 12.46 | 11.93 | 11.08 | 11.09 | 10.60 |